Oruka Therapeutics, Inc.

Healthcare · Biotechnology · United States

Last price 96.87 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 6.41B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an...